CA3210289A1 - Mage-a4 peptide-mhc antigen binding proteins - Google Patents

Mage-a4 peptide-mhc antigen binding proteins

Info

Publication number
CA3210289A1
CA3210289A1 CA3210289A CA3210289A CA3210289A1 CA 3210289 A1 CA3210289 A1 CA 3210289A1 CA 3210289 A CA3210289 A CA 3210289A CA 3210289 A CA3210289 A CA 3210289A CA 3210289 A1 CA3210289 A1 CA 3210289A1
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
seq
domain
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3210289A
Other languages
English (en)
French (fr)
Inventor
Anna Maria SOBIERAJ
Fabian Bert SCHEIFELE
Stephanie JUNGMICHEL
Leonardo Borras
Christian Valdemar Vinge LEISNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cdr-Life AG
Original Assignee
Cdr-Life AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cdr-Life AG filed Critical Cdr-Life AG
Publication of CA3210289A1 publication Critical patent/CA3210289A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3210289A 2021-03-09 2022-03-09 Mage-a4 peptide-mhc antigen binding proteins Pending CA3210289A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163158691P 2021-03-09 2021-03-09
US63/158,691 2021-03-09
US202163172864P 2021-04-09 2021-04-09
US63/172,864 2021-04-09
PCT/IB2022/052119 WO2022190009A1 (en) 2021-03-09 2022-03-09 Mage-a4 peptide-mhc antigen binding proteins

Publications (1)

Publication Number Publication Date
CA3210289A1 true CA3210289A1 (en) 2022-09-15

Family

ID=80787264

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3210289A Pending CA3210289A1 (en) 2021-03-09 2022-03-09 Mage-a4 peptide-mhc antigen binding proteins

Country Status (8)

Country Link
US (2) US11912771B2 (https=)
EP (1) EP4304726A1 (https=)
JP (1) JP2024509910A (https=)
KR (1) KR20230169944A (https=)
AU (1) AU2022233285A1 (https=)
CA (1) CA3210289A1 (https=)
MX (1) MX2023010541A (https=)
WO (1) WO2022190009A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
KR20240116828A (ko) 2021-12-14 2024-07-30 씨디알-라이프 아게 이중 mhc-표적화 t 세포 관여자
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
CN119490592B (zh) * 2023-08-14 2025-11-18 东莞市朋志生物科技有限公司 一种抗κ型轻链抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199231B1 (en) 1991-05-23 2007-04-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
EP1651659A4 (en) 2003-08-07 2008-09-17 Epitomics Inc METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
IN2009DN05758A (https=) 2007-03-12 2015-07-24 Esbatech Ag
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
KR101530723B1 (ko) 2007-06-25 2015-06-22 에스바테크 - 어 노바티스 컴파니 엘엘씨 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
PL3241843T3 (pl) 2008-06-25 2021-12-27 Novartis Ag Optymalizacja rozpuszczalności cząsteczek immunowiążących
CN104004094B (zh) 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
WO2011025964A2 (en) * 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
EP2760892A1 (en) 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
PL3440105T3 (pl) 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
SMT202100564T1 (it) 2016-04-08 2022-01-10 Adaptimmune Ltd Recettori di cellule t
CA3020555A1 (en) 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
CN116987189A (zh) 2016-05-20 2023-11-03 哈普恩治疗公司 单链可变片段cd3结合蛋白质
US11590098B2 (en) * 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR20190142767A (ko) 2017-03-20 2019-12-27 제노세아 바이오사이언스, 인코퍼레이티드 치료 방법
US11497768B2 (en) 2017-06-05 2022-11-15 Mie University Antigen-binding protein that recognizes MAGE-A4-derived peptide
AU2018318303A1 (en) 2017-08-18 2020-04-09 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
US20210061914A1 (en) 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
JP7326764B2 (ja) 2018-03-09 2023-08-16 東ソー株式会社 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法
AU2019283639A1 (en) 2018-06-04 2021-01-07 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
CN108866098A (zh) 2018-07-27 2018-11-23 北京安斯晨睿生物科技有限公司 携带mage-a4突变抗原基因的重组腺相关病毒载体及其构建方法与应用
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
BR112021025548A2 (pt) 2019-06-18 2022-05-17 Regeneron Pharma Receptores de células t mage-a4 e métodos de uso dos mesmos
MX2022000896A (es) * 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN110333352A (zh) 2019-08-07 2019-10-15 基因科技（上海）股份有限公司 肿瘤相关自身抗体及肿瘤标志物联合检测试剂盒
CR20220256A (es) 2019-12-18 2022-08-31 Hoffmann La Roche Anticuerpos que se unen a hla-a2/mage-a4
CN115803340A (zh) 2020-04-24 2023-03-14 纪念斯隆凯特琳癌症中心 抗cd3抗体及其用途
CN116096754A (zh) 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
JP2023526259A (ja) 2020-05-13 2023-06-21 アダプティミューン・リミテッド がんまたは腫瘍の治療の方法
US20230190803A1 (en) 2020-05-13 2023-06-22 Adaptimmune Limited Method of treatment of cancer or tumour
CN114524878B (zh) 2020-11-23 2024-08-02 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
CA3217914A1 (en) 2021-05-04 2022-11-10 Kevin BRAY Chimeric antigen receptors with mage-a4 specificity and uses thereof
US20240218065A1 (en) 2021-06-15 2024-07-04 Shenghe (China) Biopharmaceutical Co. Multispecific antigen-binding protein and use thereof
US20240336682A1 (en) 2021-08-02 2024-10-10 Shenghe (China) Biopharmaceutical Co., Ltd. Multispecific antigen-binding protein and use thereof
US20240327543A1 (en) 2021-08-02 2024-10-03 Shenghe (China) Biopharmaceutical Co., Ltd. Multispecific antigen-binding protein and use thereof
CN118043357A (zh) 2021-08-04 2024-05-14 阿布普罗公司 Cd3靶向抗体及其用途
IL311039A (en) 2021-09-17 2024-04-01 Adimab Llc Anti-cd3 antibodies

Also Published As

Publication number Publication date
US11912771B2 (en) 2024-02-27
KR20230169944A (ko) 2023-12-18
US20220380472A1 (en) 2022-12-01
EP4304726A1 (en) 2024-01-17
US20240279344A1 (en) 2024-08-22
MX2023010541A (es) 2023-11-24
JP2024509910A (ja) 2024-03-05
WO2022190009A1 (en) 2022-09-15
AU2022233285A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US11912771B2 (en) MAGE-A4 peptide-MHC antigen binding proteins
US20190367612A1 (en) Anti-gprc5d antibody and molecule containing same
US12435444B2 (en) Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
JP7457822B2 (ja) 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用
CN112119099A (zh) 三特异性抗原结合蛋白
US20230406922A1 (en) Humanized cd19 antibody and use thereof
US20250144141A1 (en) Mage-a4 peptide dual t cell engagers
KR20230074192A (ko) 인간 cd3 엡실론에 결합하는 신규의 인간 항체
TWI714895B (zh) 抗csf-1r抗體、其抗原結合片段及其醫藥用途
WO2022117032A1 (zh) 抗cd22的纳米抗体及其用途
US20250002586A1 (en) Dual mhc-targeting t cell engager
KR20250143344A (ko) 항-cdh6 항체 및 이의 용도
US20250333514A1 (en) Antigen binding proteins targeting an hla-restricted prame peptide
CN117751146A (zh) Mage-a4肽-mhc抗原结合蛋白
WO2025210181A1 (en) Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
HK40075692A (en) Novel anti-tcr delta variable 1 antibodies

Legal Events

Date Code Title Description
R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20241010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241121

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250205

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250205

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260224

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260304

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260304

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260305

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260317

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260317

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260317

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260317

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260317

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260317

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260402